Platinum-Resistant Fallopian Tube Carcinoma

Platinum-Resistant Fallopian Tube Carcinoma — Trials · CancerIndex

Clinical trials

Registered studies

30 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 15
Recruiting: 5
Ph III recruiting: 1
Growth YoY: —
Industry share: 27%
Top sponsor: National Cancer Institute (NCI)
Termination share: —

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (7)

clinicaltrialsPublishedShowing 1–15 of 15 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT07708753	A Study of SYS6043 in Platinum-Resistant, Advanced Ovarian, Primary Peritoneal, or Fallopian Tube Cancers	recruiting	Phase 3	460	CSPC Megalith Biopharmaceutical Co.,Ltd.INDUSTRY	1	Sep 23, 2026	clinicaltrials
NCT02839707	Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer	active not recruiting	Phase 2 / Phase 3	444	National Cancer Institute (NCI)NIH	2	Aug 28, 2026